Timothy J Daskivich1, I-Chun Thomas2, Michael Luu3, Jeremy B Shelton4, Danil V Makarov5, Ted A Skolarus6, John T Leppert7,8. 1. Division of Urology, Cedars-Sinai Medical Center, Los Angeles, California. 2. Veterans Affairs Palo Alto Health Care System, Palo Alto, California. 3. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. 4. Department of Urology, University of California-Los Angeles and West Los Angeles Veterans Affairs Medical Center, Los Angeles, California. 5. Departments of Urology and Population Health, New York University Langone Medical Center and Veterans Affairs New York Harbor Healthcare System, New York, New York. 6. Department of Urology, University of Michigan and Veterans Affairs Ann Arbor Healthcare System, Center for Clinical Management and Research, Ann Arbor, Michigan. 7. Veterans Affairs Center for Innovation to Implementation, Palo Alto, California. 8. Departments of Urology and Medicine, Stanford University, Stanford, California.
Abstract
PURPOSE: Accurate assessment of life expectancy is critical to treatment decision making in men with prostate cancer. We sought to externally validate the PCCI (Prostate Cancer Comorbidity Index) to predict long-term mortality in men with prostate cancer and make it operational using claims data. MATERIALS AND METHODS: We performed an observational study of 181,009 men with prostate cancer in the Veterans Affairs Health System who were diagnosed from 2000 to 2013. Overall mortality across the PCCI scores was analyzed using Kaplan-Meier and Cox proportional hazards analysis. Discrimination and calibration were measured using the C-index and the mean prediction error, respectively. RESULTS: Among men with a PCCI score of 0, 1-2, 3-4, 5-6, 7-9 and 10 or greater the 10-year overall mortality rate was 15%, 26%, 36%, 41%, 52% and 69%, respectively. Multivariable Cox analysis showed an increasing hazard of mortality with higher PCCI scores, including 1.22 (95% CI 1.18-1.27), 1.69 (95% CI 1.61-1.76), 2.08 (95% CI 2.00-2.17), 2.88 (95% CI 2.76-3.00) and 4.50 (95% CI 4.32-4.69) for a score of 1 to 2, 3 to 4, 5 to 6, 7 to 9 and 10 or greater, respectively. The C-index to predict overall mortality was 0.773. The mean absolute error to predict 10-year overall mortality was 0.032. Of the men with clinically localized disease, Gleason 6 or less with less than 10-year life expectancy and Gleason 7 or less with life expectancy less than 5 years as defined by the PCCI 3,999 of 12,185 (33%) and 1,038 of 3,930 (26%), respectively, underwent definitive local treatment. CONCLUSIONS: The PCCI is a claims based, externally validated tool to predict mortality in men with prostate cancer. Integrating the PCCI into clinical pathways may improve prostate cancer management through more accurate assessment of life expectancy.
PURPOSE: Accurate assessment of life expectancy is critical to treatment decision making in men with prostate cancer. We sought to externally validate the PCCI (Prostate Cancer Comorbidity Index) to predict long-term mortality in men with prostate cancer and make it operational using claims data. MATERIALS AND METHODS: We performed an observational study of 181,009 men with prostate cancer in the Veterans Affairs Health System who were diagnosed from 2000 to 2013. Overall mortality across the PCCI scores was analyzed using Kaplan-Meier and Cox proportional hazards analysis. Discrimination and calibration were measured using the C-index and the mean prediction error, respectively. RESULTS: Among men with a PCCI score of 0, 1-2, 3-4, 5-6, 7-9 and 10 or greater the 10-year overall mortality rate was 15%, 26%, 36%, 41%, 52% and 69%, respectively. Multivariable Cox analysis showed an increasing hazard of mortality with higher PCCI scores, including 1.22 (95% CI 1.18-1.27), 1.69 (95% CI 1.61-1.76), 2.08 (95% CI 2.00-2.17), 2.88 (95% CI 2.76-3.00) and 4.50 (95% CI 4.32-4.69) for a score of 1 to 2, 3 to 4, 5 to 6, 7 to 9 and 10 or greater, respectively. The C-index to predict overall mortality was 0.773. The mean absolute error to predict 10-year overall mortality was 0.032. Of the men with clinically localized disease, Gleason 6 or less with less than 10-year life expectancy and Gleason 7 or less with life expectancy less than 5 years as defined by the PCCI 3,999 of 12,185 (33%) and 1,038 of 3,930 (26%), respectively, underwent definitive local treatment. CONCLUSIONS: The PCCI is a claims based, externally validated tool to predict mortality in men with prostate cancer. Integrating the PCCI into clinical pathways may improve prostate cancer management through more accurate assessment of life expectancy.
Entities:
Keywords:
United States Department of Veterans Affairs; comorbidity; life expectancy; mortality; prostatic neoplasms
Authors: Gregory T Chesnut; Amy L Tin; Katherine A Fleshner; Nicole E Benfante; Andrew J Vickers; James A Eastham; Daniel D Sjoberg; Sigrid V Carlsson Journal: Prostate Cancer Prostatic Dis Date: 2021-11-03 Impact factor: 5.554
Authors: Ericka M Sohlberg; I-Chun Thomas; Jaden Yang; Kristopher Kapphahn; Timothy J Daskivich; Ted A Skolarus; Jeremy B Shelton; Danil V Makarov; Jonathan Bergman; Christine Ko Bang; Mary K Goldstein; Todd H Wagner; James D Brooks; Manisha Desai; John T Leppert Journal: Urol Oncol Date: 2020-07-13 Impact factor: 3.498
Authors: Kristina Vaculik; Michael Luu; Lauren E Howard; William Aronson; Martha Terris; Christopher Kane; Christopher Amling; Matthew Cooperberg; Stephen J Freedland; Timothy J Daskivich Journal: JAMA Netw Open Date: 2021-06-01
Authors: Ryan M Fiano; Gregory S Merrick; Kim E Innes; Malcolm D Mattes; Traci J LeMasters; Chan Shen; Usha Sambamoorthi Journal: Cancer Med Date: 2020-07-06 Impact factor: 4.452
Authors: David Merola; Sebastian Schneeweiss; Sushama K Sreedhara; Luke E Zabotka; Kenneth Quinto; John Concato; Shirley V Wang Journal: JNCI Cancer Spectr Date: 2022-08-10
Authors: Simon John Christoph Soerensen; I-Chun Thomas; Bogdana Schmidt; Timothy J Daskivich; Ted A Skolarus; Christian Jackson; Thomas F Osborne; Glenn M Chertow; James D Brooks; David H Rehkopf; John T Leppert Journal: Urology Date: 2021-06-15 Impact factor: 2.633